biote (NASDAQ:BTMD) and Cronos Group (NASDAQ:CRON) Financial Review

biote (NASDAQ:BTMDGet Rating) and Cronos Group (NASDAQ:CRONGet Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.


This table compares biote and Cronos Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
biote N/A -20.05% 5.99%
Cronos Group -235.72% -16.29% -15.66%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for biote and Cronos Group, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
biote 0 0 4 0 3.00
Cronos Group 0 4 4 0 2.50

biote presently has a consensus target price of $10.25, indicating a potential upside of 148.18%. Cronos Group has a consensus target price of $4.09, indicating a potential upside of 33.31%. Given biote’s stronger consensus rating and higher probable upside, equities analysts plainly believe biote is more favorable than Cronos Group.

Valuation and Earnings

This table compares biote and Cronos Group’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
biote N/A N/A $11.11 million N/A N/A
Cronos Group $74.43 million 15.60 -$396.11 million ($0.60) -5.12

biote has higher earnings, but lower revenue than Cronos Group.

Risk and Volatility

biote has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.

Insider and Institutional Ownership

2.1% of biote shares are held by institutional investors. Comparatively, 12.1% of Cronos Group shares are held by institutional investors. 6.0% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

About biote

(Get Rating)

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.

About Cronos Group

(Get Rating)

Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. It also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with's FREE daily email newsletter.